Skip to Content
Merck
CN

59589-U

Discovery® C8 (5 µm) HPLC Columns

L × I.D. 2 cm × 4 mm Supelguard Guard Cartridge, pkg of 2 ea, Guard Cartridge holder required for use

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52
L × i.d.:
2 cm × 4 mm
Particle size:
5 μm
Matrix:
fully porous particle
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Discovery® C8 Supelguard Guard Cartridge Kit, 5 μm particle size, L × I.D. 2 cm × 4 mm, contains 2 nuts, 2 ferrules, 5cm tubing, 1 guard cartridge and 1 guard holder

particle size

5 μm

operating pH

2-8

application(s)

food and beverages

separation technique

reversed phase

material

stainless steel column

product line

Discovery®

feature

endcapped

packaging

pkg of 1 kit

technique(s)

HPLC: suitable
LC/MS: suitable

L × I.D.

2 cm × 4 mm

matrix

fully porous particle

Quality Level

Other Notes

Discover LiChropur reagents ideal for HPLC or LC-MS analysis
Kit includes one cartridge, a stand-along holder, a piece of tubing and 2 nuts and ferrules.

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Bo-Rui Kang et al.
Bioorganic & medicinal chemistry letters, 25(24), 5808-5812 (2015-11-08)
2-Benzylisoquinolin-1(2H)-ones has been proposed as vasodilative agents on the basis of scaffold hopping. In the present study, a series of 2-benzylisoquinolin-1(2H)-ones were synthesized. Their vasodilative effects were evaluated by wire myograph on isolated rat mesenteric arterial ring induced contraction with
Scott C Bell et al.
Pharmacology & therapeutics, 145, 19-34 (2014-06-17)
With the discovery of the CFTR gene in 1989, the search for therapies to improve the basic defects of cystic fibrosis (CF) commenced. Pharmacological manipulation provides the opportunity to enhance CF transmembrane conductance regulator (CFTR) protein synthesis and/or function. CFTR
Simeon Grazio et al.
Clinical and experimental rheumatology, 31(5), 665-671 (2013-06-07)
Using proteomic approach in this study, we sought to identify proteins with heparin affinity associated with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and non-inflammatory arthritis (NIA). Plasma samples from adult RA, PsA and NIA patients, 20 of each, were collected.
M Q Zhang et al.
Die Pharmazie, 46(10), 687-700 (1991-10-01)
The rapid growth in the quinolone research changed the whole face of the previous SAR concepts. So far structural modifications at all positions of the quinolone nucleus except the 4-oxo group have successfully lead to the discovery of potent antimicrobial
Hugo M Botelho et al.
Scientific reports, 5, 9038-9038 (2015-03-13)
Plasma membrane proteins are essential molecules in the cell which mediate interactions with the exterior milieu, thus representing key drug targets for present pharma. Not surprisingly, protein traffic disorders include a large range of diseases sharing the common mechanism of

Related Content

Discovery C18 and C8 HPLC Columns products offered

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service